Detalhe da pesquisa
1.
Clinical Impact of Colonization with Multidrug-Resistant Organisms on Outcome after Autologous Stem Cell Transplantation: A Retrospective Single-Center Study.
Biol Blood Marrow Transplant
; 23(9): 1455-1462, 2017 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-28528711
2.
Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany.
Haematologica
; 105(12): 2872-2878, 2020 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33256391
3.
Cytokine-responsive T- and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patients.
Leukemia
; 38(1): 168-180, 2024 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38049509
4.
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.
Leukemia
; 38(3): 640-647, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38062124
5.
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.
Lancet Haematol
; 11(2): e101-e113, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38302221
6.
The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling.
Eur J Haematol
; 90(4): 263-72, 2013 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-23311753
7.
The MYC-Regulated RNA-Binding Proteins hnRNPC and LARP1 Are Drivers of Multiple Myeloma Cell Growth and Disease Progression and Negatively Predict Patient Survival.
Cancers (Basel)
; 15(23)2023 Nov 21.
Artigo
Inglês
| MEDLINE | ID: mdl-38067212
8.
The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases.
Eur J Haematol
; 88(5): 406-15, 2012 May.
Artigo
Inglês
| MEDLINE | ID: mdl-22309072
9.
CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma.
Oncoimmunology
; 11(1): 2081415, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-35694192
10.
COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term view.
J Mol Med (Berl)
; 100(3): 463-470, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34657968
11.
Identification of the Cysteine Protease Legumain as a Potential Chronic Hypoxia-Specific Multiple Myeloma Target Gene.
Cells
; 11(2)2022 01 15.
Artigo
Inglês
| MEDLINE | ID: mdl-35053409
12.
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Lancet Haematol
; 9(11): e810-e821, 2022 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-36328040
13.
Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
Eur J Haematol
; 84(4): 337-44, 2010 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-20028416
14.
BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma.
Eur J Haematol
; 85(2): 99-107, 2010 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-20374272
15.
Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
Exp Cell Res
; 315(14): 2471-8, 2009 Aug 15.
Artigo
Inglês
| MEDLINE | ID: mdl-19410573
16.
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Eur J Haematol
; 82(6): 440-9, 2009 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-19220424
17.
CD8+ CD28- regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study.
Leukemia
; 2024 Jun 03.
Artigo
Inglês
| MEDLINE | ID: mdl-38830959
18.
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Eur J Haematol
; 80(2): 133-42, 2008 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-18005386
19.
Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma.
Front Immunol
; 9: 2743, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-30542346
20.
Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM.
Blood Adv
; 7(3): 379-383, 2023 02 14.
Artigo
Inglês
| MEDLINE | ID: mdl-35914229